VivoSeq
Oncology

Esophagus Cancer

2

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Esophagus Cancer is an early-stage landscape with 2 programs across 3 companies. The most active players are Avyxa, Teva, Sanofi.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

100/100

Completion Rate

71/100

Attrition Rate

15/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Avyxa

1 program

Phase 1Teva logo

Teva

1 program

Phase 1Sanofi logo

Sanofi

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 12

Carboplatin

Avyxa

Paclitaxel

Teva

Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

13

clinical trials

Completed5 · 38%
Unknown status4 · 31%
Terminated2 · 15%
Active, not recruiting1 · 8%
Recruiting1 · 8%

Clinical Trials

Trial Activity

13 trials

Multimodal Deep Learning for Predicting Treatment Response to Neoadjuvant Chemoimmunotherapy in Esophageal Cancer
Recruiting·CCentral South University·N/A·NCT07063901·200 enrolled
Phase I Study of Radiation Dose Intensification With Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Concurrent Carboplatin and Paclitaxel for Inoperable Esophageal Cancer
Active, not recruiting·WWashington University School of Medicine·Phase 1·NCT04046575·12 enrolled
Oxaliplatin and 5-Fluorouracil With or Without Docetaxel in Elderly Patients (>65 y) With Stomach and Esophagus Cancer
Completed·—·Phase 2·NCT00737373·143 enrolled
Tumor Antigen-sensitized DC Vaccine As an Adjuvant Therapy for Esophagus Cancer
Completed·SSichuan University·Phase 1·NCT05023928·25 enrolled
99mTc-3PRGD2 SPECT/CT in Esophagus Cancer Patients
Completed·FFirst Affiliated Hospital of Fujian Medical University·Phase 1·NCT02744729·29 enrolled
Oxaliplatin in Esophagus Cancer (Advanced) 1st Line
Completed·Sanofi logoSanofi·Phase 2·NCT00259402·41 enrolled
Preoperative Therapy With Oxaliplatin/Docetaxel/Capecitabine and Radiation in Resectable Esophagus Cancer
Completed·SSCRI Development Innovations, LLC·Phase 1/2·NCT00193128·59 enrolled
A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers
Terminated·UUniversity of Pittsburgh·Phase 2·NCT00177255·40 enrolled
Pre-op Chemo-RT w/CDDP/5FU vs Chemo w/ Docetaxel/Irinotecan in PET Non Responder Resectable Esophagus Cancer
Terminated·KKing Faisal Specialist Hospital & Research Center·Phase 2·NCT01608464·170 enrolled
Clinical Trial of Qizhu Yuling Prescription in the Prevention and Treatment of Esophagus Cancer
Unknown status·—·N/A·NCT05626309·310 enrolled
Apatinib Treatment for Advanced Esophagus Cancer
Unknown status·HHenan Cancer Hospital·Phase 2·NCT03170310·60 enrolled
Apatinib as First -Line Treatment for Advanced Esophagus Cancer
Unknown status·—·Phase 2·NCT03542422·50 enrolled
DC Vaccine Combined With CIK Cells in Patients With Esophagus Cancer
Unknown status·—·Phase 1/2·NCT02693236·30 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)